oral drug
Pfizer-backed CellCentric Secures $120M for Myeloma Drug Trials
CellCentric; Pfizer; multiple myeloma; Series C funding; inobrodib; p300/CBP inhibitor; oral drug; clinical trials; phase 2/3; accelerated approval
Lilly’s Muvalaplin Shows Promising Results in Reducing Lipoprotein(a) Levels in Adults at High Risk for Cardiovascular Events
Muvalaplin, Lipoprotein(a) [Lp(a)], Cardiovascular risk, Oral drug, Phase II trial, Eli Lilly, Cholesterol reduction